Published in J Clin Microbiol on January 23, 2013
Phylogeography and evolutionary history of hepatitis B virus genotype F in Brazil. Virol J (2013) 0.76
Sequence conservation of the region targeted by the Abbott RealTime HCV viral load assay. J Clin Microbiol (2014) 0.75
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol (2007) 2.40
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther (2007) 1.93
Resistance to integrase inhibitors. Viruses (2010) 1.75
Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res (2010) 1.53
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol (2008) 1.32
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol (2009) 1.25
Hepatitis B virus genetic diversity. J Med Virol (2006) 1.21
Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat (2007) 1.06
Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B. J Clin Microbiol (2008) 1.04
Deletions in the hepatitis B virus small envelope protein: effect on assembly and secretion of surface antigen particles. J Virol (1992) 1.01
A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion (2010) 0.97
Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient. J Clin Microbiol (2009) 0.93
The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J Med Virol (2006) 0.88
Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance. J Clin Microbiol (2010) 0.88
Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay. J Clin Microbiol (2006) 0.88
Meeting the challenge of HIV diversity: strategies to mitigate the impact of HIV-1 genetic heterogeneity on performance of nucleic acid testing assays. Clin Lab (2012) 0.82
The challenge of HIV-1 genetic diversity: discordant CD4+ T-Cell count and viral load in an untreated patient infected with a subtype F strain. J Acquir Immune Defic Syndr (2009) 0.82
Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection. J Infect Chemother (2011) 0.78
Evidence for positive epistasis in HIV-1. Science (2004) 4.12
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis (2003) 2.30
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol (2007) 2.14
Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev (2010) 1.89
Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther (2004) 1.84
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis (2005) 1.81
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem (2003) 1.66
Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology (2009) 1.60
Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol (2004) 1.55
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother (2004) 1.54
The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr (2008) 1.46
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol (2008) 1.45
Confirmation of putative HIV-1 group P in Cameroon. J Virol (2010) 1.36
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther (2010) 1.15
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother (2007) 1.13
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther (2008) 1.10
Molecular beacons as diagnostic tools: technology and applications. Clin Chem Lab Med (2003) 1.08
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob Agents Chemother (2010) 1.08
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. J Virol (2005) 1.05
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother (2007) 1.05
Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol (2007) 0.99
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother (2012) 0.99
HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res Hum Retroviruses (2007) 0.96
In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother (2005) 0.96
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. J Clin Microbiol (2013) 0.95
Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol (2010) 0.95
Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion (2008) 0.93
Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses (2009) 0.92
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. Clin Infect Dis (2005) 0.89
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS (2007) 0.88
Possible origins and evolution of the hepatitis B virus (HBV). Semin Cancer Biol (2013) 0.88
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology (2008) 0.86
Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol (2010) 0.86
Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol (2010) 0.86
HIV global surveillance: foundation for retroviral discovery and assay development. J Med Virol (2006) 0.85
Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. J Med Virol (2011) 0.84
Near full-length genome characterization of an HIV type 1 CRF25_cpx strain from Cameroon. AIDS Res Hum Retroviruses (2008) 0.83
The challenge of HIV-1 genetic diversity: discordant CD4+ T-Cell count and viral load in an untreated patient infected with a subtype F strain. J Acquir Immune Defic Syndr (2009) 0.82
Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin Infect Dis (2003) 0.81
Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis (2013) 0.80
Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon. AIDS Res Hum Retroviruses (2007) 0.80
Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir. J Virol Methods (2013) 0.79
HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology (2010) 0.79
Analysis of PTAP duplications in the gag p6 region of subtype C HIV type 1. AIDS Res Hum Retroviruses (2005) 0.79
Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS (2006) 0.78
Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits. Antiviral Res (2011) 0.78
Sequencing and phylogenetic analysis of near full-length HIV-1 subtypes A, B, G and unique recombinant AC and AD viral strains identified in South Africa. AIDS Res Hum Retroviruses (2015) 0.77
Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations. J Clin Microbiol (2011) 0.77
Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon. AIDS Res Hum Retroviruses (2012) 0.76
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity. J Clin Microbiol (2015) 0.75
Sequence conservation of the region targeted by the Abbott RealTime HCV viral load assay. J Clin Microbiol (2014) 0.75
Hepatitis B surface antigen and Hepatitis B RNA changes in HIV/HBV Co-infected participants receiving HBV-active antiretroviral therapy for 144 weeks. AIDS (2022) 0.75